Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shu Gan Ning injection for liver injury caused by chronic hepatitis B
ChiCTR1900020929Phase 4Not yet recruiting
- Sponsor
- Beijing YouAn Hospital
- Start
- Oct 2018
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Shuganning injection in Chronic Hepatitis B (CHB) (2 arms), sponsored by Beijing YouAn Hospital. Primary endpoints: total bilirubin, direct bilirubin and 6 more. Planned start Oct 2018; status: not yet recruiting.
02
Drugs
Shuganning injection
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR1900020929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900020929.